<?xml version='1.0' encoding='utf-8'?>
<document id="30798679"><sentence text="HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases."><entity charOffset="66-78" id="DDI-PubMed.30798679.s1.e0" text="Elvitegravir" /><entity charOffset="79-89" id="DDI-PubMed.30798679.s1.e1" text="Cobicistat" /><entity charOffset="90-103" id="DDI-PubMed.30798679.s1.e2" text="Emtricitabine" /><entity charOffset="104-125" id="DDI-PubMed.30798679.s1.e3" text="Tenofovir Alafenamide" /><entity charOffset="130-137" id="DDI-PubMed.30798679.s1.e4" text="Calcium" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e0" e2="DDI-PubMed.30798679.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e0" e2="DDI-PubMed.30798679.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e0" e2="DDI-PubMed.30798679.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e0" e2="DDI-PubMed.30798679.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e0" e2="DDI-PubMed.30798679.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e1" e2="DDI-PubMed.30798679.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e1" e2="DDI-PubMed.30798679.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e1" e2="DDI-PubMed.30798679.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e1" e2="DDI-PubMed.30798679.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e2" e2="DDI-PubMed.30798679.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e2" e2="DDI-PubMed.30798679.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e2" e2="DDI-PubMed.30798679.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e3" e2="DDI-PubMed.30798679.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30798679.s1.e3" e2="DDI-PubMed.30798679.s1.e4" /></sentence><sentence text="Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance"><entity charOffset="0-12" id="DDI-PubMed.30798679.s2.e0" text="Elvitegravir" /><entity charOffset="13-23" id="DDI-PubMed.30798679.s2.e1" text="cobicistat" /><entity charOffset="24-37" id="DDI-PubMed.30798679.s2.e2" text="emtricitabine" /><entity charOffset="38-59" id="DDI-PubMed.30798679.s2.e3" text="tenofovir alafenamide" /><entity charOffset="67-70" id="DDI-PubMed.30798679.s2.e4" text="TAF" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e0" e2="DDI-PubMed.30798679.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e0" e2="DDI-PubMed.30798679.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e0" e2="DDI-PubMed.30798679.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e0" e2="DDI-PubMed.30798679.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e0" e2="DDI-PubMed.30798679.s2.e4" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e1" e2="DDI-PubMed.30798679.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e1" e2="DDI-PubMed.30798679.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e1" e2="DDI-PubMed.30798679.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e1" e2="DDI-PubMed.30798679.s2.e4" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e2" e2="DDI-PubMed.30798679.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e2" e2="DDI-PubMed.30798679.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e2" e2="DDI-PubMed.30798679.s2.e4" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e3" e2="DDI-PubMed.30798679.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30798679.s2.e3" e2="DDI-PubMed.30798679.s2.e4" /></sentence><sentence text=" We report a potential drug-drug interaction in 2 female patients both receiving treatment for HIV and cerebral toxoplasmosis: one case between E/C/F/TAF with calcium carbonate and a second case involving leucovorin as calcium salt"><entity charOffset="159-176" id="DDI-PubMed.30798679.s3.e0" text="calcium carbonate" /><entity charOffset="205-215" id="DDI-PubMed.30798679.s3.e1" text="leucovorin" /><entity charOffset="219-226" id="DDI-PubMed.30798679.s3.e2" text="calcium" /><entity charOffset="150-156" id="DDI-PubMed.30798679.s3.e3" text="TAF" /><pair ddi="false" e1="DDI-PubMed.30798679.s3.e3" e2="DDI-PubMed.30798679.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30798679.s3.e3" e2="DDI-PubMed.30798679.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30798679.s3.e3" e2="DDI-PubMed.30798679.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30798679.s3.e3" e2="DDI-PubMed.30798679.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30798679.s3.e0" e2="DDI-PubMed.30798679.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30798679.s3.e0" e2="DDI-PubMed.30798679.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30798679.s3.e0" e2="DDI-PubMed.30798679.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30798679.s3.e1" e2="DDI-PubMed.30798679.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30798679.s3.e1" e2="DDI-PubMed.30798679.s3.e2" /></sentence><sentence text=" Both cases resulted in rise in HIV RNA levels and emergence of M184 V mutation and resistance to elvitegravir and raltegravir"><entity charOffset="115-126" id="DDI-PubMed.30798679.s4.e0" text="raltegravir" /></sentence><sentence text=" To the best of our knowledge, these 2 cases are the first reports of rapid emergence of mutation from coadministration of E/C/F/TAF and calcium"><entity charOffset="137-144" id="DDI-PubMed.30798679.s5.e0" text="calcium" /><entity charOffset="129-135" id="DDI-PubMed.30798679.s5.e1" text="TAF" /><pair ddi="false" e1="DDI-PubMed.30798679.s5.e1" e2="DDI-PubMed.30798679.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30798679.s5.e1" e2="DDI-PubMed.30798679.s5.e0" /></sentence><sentence text="" /></document>